Medical Developments International Ltd. engages in the manufacture and distribution of pharmaceutical drugs, medical, and veterinary equipment. The firm operates in two segments: Pain Management and Respiratory. The Pain Management segment is engaged in the supply of analgesia for acute and procedural pain. The firm manufactures an inhaled analgesic, Penthrox (the Green Whistle), at manufacturing facilities at Scoresby and Springvale in Victoria, Australia. Penthrox is sold into domestic and international markets through distribution partnerships and direct in-market capability. The Respiratory segment is a supplier of respiratory products including asthma and chronic obstructive pulmonary disease (COPD) space chambers, peak flow meters, portable nebulizers and silicone face masks. The respiratory supplies into Australia, the United States of America, Europe, and Asia through partnerships with distributors.
Medical Developments International Limited의 주요 재무제표는 무엇인가요?
최신 재무제표(Form-10K)에 따르면, Medical Developments International Limited의 총 자산은 $66이며, 순손실입니다.
MDDVF의 주요 재무 비율은 무엇인가요?
Medical Developments International Limited의 유동비율은 6이고, 순이익률은 0, 주당 매출은 $0.34입니다.
Medical Developments International Limited의 매출은 부문 또는 지역별로 어떻게 나뉘나요?
Medical Developments International Limited 주요 수익원은 Pain Management이며, 최신 수익 발표에서 수익은 21,296,000입니다. 지역별로는 Australia이 Medical Developments International Limited의 주요 시장이며, 수익은 15,364,000입니다.
Medical Developments International Limited은 수익성이 있나요?
no, 최신 재무제표에 따르면 Medical Developments International Limited의 순손실은 $0입니다.
Medical Developments International Limited에 부채가 있나요?
예, Medical Developments International Limited의 부채는 11입니다.
Medical Developments International Limited의 발행 주식은 몇 주인가요?
Medical Developments International Limited의 총 발행 주식은 112.65주입니다.